Rufinamide 400 MG Oral Tablet — RxCUI 824301
RxNorm drug concept · Semantic clinical drug
RxCUI 824301
Semantic clinical drug · SCD
● Current RxNorm concept 15 FDA products
22 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI824301
Official nameRufinamide 400 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped15
Package NDCs mapped22
Reported Medicaid activity (SDUD)35,728 prescriptions · 46 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Rufinamide: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Rufinamide — sold as Banzel — is used to help control seizures in people with Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that often starts in childhood. It's always u...
- Yes — this one really matters. Food significantly increases how much rufinamide your body absorbs, so taking it on an empty stomach means you could be getting much less of the medi...
- Do I really need to take it with food every time?
- The most common ones are drowsiness, headache, dizziness, nausea or vomiting, and feeling tired — these are annoying but generally manageable. The ones that need a call to your doc...
🕸️ Concept Web — How Rufinamide 400 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Rufinamide 400 MG Oral Tablet
RxCUI 824301 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Rufinamide
69036IN
-
Rufinamide
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Banzel
824296BN
-
Banzel
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Rufinamide Oral Tablet
824294SCDF -
Rufinamide Oral Product
1158000SCDG -
Rufinamide Pill
1158001SCDG -
Rufinamide Oral Tablet [Banzel]
824298SBDF -
Banzel Oral Product
1168002SBDG -
Banzel Pill
1168003SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Rufinamide Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Rufinamide 400 MG
824300SCDC -
Rufinamide 400 MG Oral Tablet [Banzel]
824303SBD -
Rufinamide 400 MG [Banzel]
824302SBDC
-
Rufinamide 400 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Rufinamide 400 MG
SCDC · 824300 -
Rufinamide Oral Tablet
SCDF · 824294 -
Rufinamide Oral Product
SCDG · 1158000 -
Rufinamide Pill
SCDG · 1158001
Brand-Name Concepts
-
Rufinamide 400 MG Oral Tablet [Banzel]
SBD · 824303 -
Rufinamide 400 MG [Banzel]
SBDC · 824302 -
Rufinamide Oral Tablet [Banzel]
SBDF · 824298 -
Banzel Oral Product
SBDG · 1168002 -
Banzel Pill
SBDG · 1168003 -
Banzel
BN · 824296
📦 FDA Products & Package NDCs
15 products · 22 package NDCs
22 package NDCs map to RxCUI 824301 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00054-0425-23 | 120 TABLET, FILM COATED in 1 BOTTLE (0054-0425-23) | Rufinamide | Hikma Pharmaceuticals USA Inc. | 2021-05-30 |
| 00054-0426-23 | 120 TABLET, FILM COATED in 1 BOTTLE (0054-0426-23) | Rufinamide | Hikma Pharmaceuticals USA Inc. | 2021-05-30 |
| 31722-0598-12 | 120 TABLET, FILM COATED in 1 BOTTLE (31722-598-12) | Rufinamide | Camber Pharmaceuticals, Inc. | 2021-05-11 |
| 31722-0598-30 | 30 TABLET, FILM COATED in 1 BOTTLE (31722-598-30) | Rufinamide | Camber Pharmaceuticals, Inc. | 2021-05-11 |
| 31722-0599-12 | 120 TABLET, FILM COATED in 1 BOTTLE (31722-599-12) | Rufinamide | Camber Pharmaceuticals, Inc. | 2021-05-11 |
| 31722-0599-30 | 30 TABLET, FILM COATED in 1 BOTTLE (31722-599-30) | Rufinamide | Camber Pharmaceuticals, Inc. | 2021-05-11 |
| 42571-0391-12 | 120 TABLET in 1 BOTTLE (42571-391-12) | RUFINAMIDE | Micro Labs Limited | 2023-07-01 |
| 42571-0392-12 | 120 TABLET in 1 BOTTLE (42571-392-12) | RUFINAMIDE | Micro Labs Limited | 2023-07-01 |
| 59651-0616-08 | 120 TABLET, FILM COATED in 1 BOTTLE (59651-616-08) | Rufinamide | Aurobindo Pharma Limited | 2023-06-16 |
| 59651-0617-08 | 120 TABLET, FILM COATED in 1 BOTTLE (59651-617-08) | Rufinamide | Aurobindo Pharma Limited | 2023-06-16 |
| 62856-0582-04 | 4 TABLET, FILM COATED in 1 BOTTLE (62856-582-04) | Banzel | Eisai Inc. | 2018-08-08 |
| 62856-0582-52 | 120 TABLET, FILM COATED in 1 BOTTLE (62856-582-52) | Banzel | Eisai Inc. | 2008-11-14 |
| 62856-0583-14 | 14 TABLET, FILM COATED in 1 BOTTLE (62856-583-14) | Banzel | Eisai Inc. | 2018-08-08 |
| 62856-0583-52 | 120 TABLET, FILM COATED in 1 BOTTLE (62856-583-52) | Banzel | Eisai Inc. | 2008-11-14 |
| 62856-0584-46 | 1 BOTTLE in 1 CARTON (62856-584-46) / 460 mL in 1 BOTTLE | Banzel | Eisai Inc. | 2011-03-03 |
| 68180-0803-16 | 120 TABLET, FILM COATED in 1 BOTTLE (68180-803-16) | RUFINAMIDE | Lupin Pharmaceuticals, Inc. | 2022-11-28 |
| 68180-0804-16 | 120 TABLET, FILM COATED in 1 BOTTLE (68180-804-16) | RUFINAMIDE | Lupin Pharmaceuticals, Inc. | 2022-11-28 |
| 68462-0713-05 | 500 TABLET, FILM COATED in 1 BOTTLE (68462-713-05) | rufinamide | Glenmark Pharmaceuticals Inc., USA | 2016-05-16 |
| 68462-0713-08 | 120 TABLET, FILM COATED in 1 BOTTLE (68462-713-08) | rufinamide | Glenmark Pharmaceuticals Inc., USA | 2016-05-16 |
| 68462-0713-30 | 30 TABLET, FILM COATED in 1 BOTTLE (68462-713-30) | rufinamide | Glenmark Pharmaceuticals Inc., USA | 2016-05-16 |
| 68462-0714-05 | 500 TABLET, FILM COATED in 1 BOTTLE (68462-714-05) | rufinamide | Glenmark Pharmaceuticals Inc., USA | 2016-05-16 |
| 68462-0714-08 | 120 TABLET, FILM COATED in 1 BOTTLE (68462-714-08) | rufinamide | Glenmark Pharmaceuticals Inc., USA | 2016-05-16 |
Observed labelers:
Eisai Inc. (5) ·
Glenmark Pharmaceuticals Inc., USA (5) ·
Camber Pharmaceuticals, Inc. (4) ·
Aurobindo Pharma Limited (2) ·
Hikma Pharmaceuticals USA Inc. (2) ·
Lupin Pharmaceuticals, Inc. (2)
· +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.